Corresponding factor inhibitors (TNF-α inhibitors and IL-17 inhibitors) may also play a role in the treatment of COVID-19, achieving the treatment strategy of “new use of old drugs” and “homotherapy for heteropathy”. This evidence concerns the gene IL17A and COVID-19.